Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 149

1.

Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study.

Mohs RC, Knopman D, Petersen RC, Ferris SH, Ernesto C, Grundman M, Sano M, Bieliauskas L, Geldmacher D, Clark C, Thal LJ.

Alzheimer Dis Assoc Disord. 1997;11 Suppl 2:S13-21.

PMID:
9236948
2.

The reliability and validity of the Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-Cog) among the elderly Chinese in Hong Kong.

Chu LW, Chiu KC, Hui SL, Yu GK, Tsui WJ, Lee PW.

Ann Acad Med Singapore. 2000 Jul;29(4):474-85.

PMID:
11056778
4.

Psychometric evaluation of ADAS-Cog and NTB for measuring drug response.

Karin A, Hannesdottir K, Jaeger J, Annas P, Segerdahl M, Karlsson P, Sjögren N, von Rosen T, Miller F.

Acta Neurol Scand. 2014 Feb;129(2):114-22. doi: 10.1111/ane.12153. Epub 2013 Jun 13.

PMID:
23763450
5.

A multicenter evaluation of new treatment efficacy instruments for Alzheimer's disease clinical trials: overview and general results. The Alzheimer's Disease Cooperative Study.

Ferris SH, Mackell JA, Mohs R, Schneider LS, Galasko D, Whitehouse PJ, Schmitt FA, Sano M, Thomas RG, Ernesto C, Grundman M, Schafer K, Thal LJ.

Alzheimer Dis Assoc Disord. 1997;11 Suppl 2:S1-12.

PMID:
9236947
6.

[Validation of the Short Cognitive Battery (B2C). Value in screening for Alzheimer's disease and depressive disorders in psychiatric practice].

Robert PH, Schuck S, Dubois B, Lépine JP, Gallarda T, Olié JP, Goni S, Troy S.

Encephale. 2003 May-Jun;29(3 Pt 1):266-72. French.

PMID:
12876552
7.

A neuropsychological test battery for use in Alzheimer disease clinical trials.

Harrison J, Minassian SL, Jenkins L, Black RS, Koller M, Grundman M.

Arch Neurol. 2007 Sep;64(9):1323-9.

PMID:
17846273
8.

The severe impairment battery: concurrent validity and the assessment of longitudinal change in Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

Schmitt FA, Ashford W, Ernesto C, Saxton J, Schneider LS, Clark CM, Ferris SH, Mackell JA, Schafer K, Thal LJ.

Alzheimer Dis Assoc Disord. 1997;11 Suppl 2:S51-6.

PMID:
9236953
9.

Cognitive factors affecting free recall, cued recall, and recognition tasks in Alzheimer's disease.

Yamagishi T, Sato T, Sato A, Imamura T.

Dement Geriatr Cogn Dis Extra. 2012 Jan;2(1):278-85. doi: 10.1159/000341600. Epub 2012 Jul 27.

10.

ADAS-cog (Alzheimer's Disease Assessment Scale-cognitive subscale)--validation of the Slovak version.

Kolibas E, Korinkova V, Novotny V, Vajdickova K, Hunakova D.

Bratisl Lek Listy. 2000;101(11):598-602.

PMID:
11218956
11.

Adding delayed recall to the Alzheimer Disease Assessment Scale is useful in studies of mild cognitive impairment but not Alzheimer disease.

Sano M, Raman R, Emond J, Thomas RG, Petersen R, Schneider LS, Aisen PS.

Alzheimer Dis Assoc Disord. 2011 Apr-Jun;25(2):122-7. doi: 10.1097/WAD.0b013e3181f883b7.

12.

Detecting treatment effects with combinations of the ADAS-cog items in patients with mild and moderate Alzheimer's disease.

Ihl R, Ferris S, Robert P, Winblad B, Gauthier S, Tennigkeit F.

Int J Geriatr Psychiatry. 2012 Jan;27(1):15-21. doi: 10.1002/gps.2679. Epub 2011 Mar 8.

PMID:
21384431
13.

Cognitive reserve and Alzheimer's disease biomarkers are independent determinants of cognition.

Vemuri P, Weigand SD, Przybelski SA, Knopman DS, Smith GE, Trojanowski JQ, Shaw LM, Decarli CS, Carmichael O, Bernstein MA, Aisen PS, Weiner M, Petersen RC, Jack CR Jr; Alzheimer's Disease Neuroimaging Initiative.

Brain. 2011 May;134(Pt 5):1479-92. doi: 10.1093/brain/awr049. Epub 2011 Apr 7.

14.

Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment.

Fleisher AS, Sowell BB, Taylor C, Gamst AC, Petersen RC, Thal LJ; Alzheimer's Disease Cooperative Study.

Neurology. 2007 May 8;68(19):1588-95. Epub 2007 Feb 7.

PMID:
17287448
15.

The relationship between extrapyramidal signs and cognitive performance in patients with Alzheimer's disease enrolled in the CERAD Study. Consortium to Establish a Registry for Alzheimer's Disease.

Clark CM, Ewbank D, Lerner A, Doody R, Henderson VW, Panisset M, Morris JC, Fillenbaum GG, Heyman A.

Neurology. 1997 Jul;49(1):70-5.

PMID:
9222172
16.

Yes/no versus forced-choice recognition memory in mild cognitive impairment and Alzheimer's disease: patterns of impairment and associations with dementia severity.

Clark LR, Stricker NH, Libon DJ, Delano-Wood L, Salmon DP, Delis DC, Bondi MW.

Clin Neuropsychol. 2012;26(7):1201-16. doi: 10.1080/13854046.2012.728626. Epub 2012 Oct 2.

17.

The cognitive subscale of Alzheimer's Disease Assessment Scale, Chinese version in staging of Alzheimer disease.

Wang H, Yu X, Li S, Chen Y, Li H, He J.

Alzheimer Dis Assoc Disord. 2004 Oct-Dec;18(4):231-5.

PMID:
15592136
18.

The cognitive subscale of the "Alzheimer's Disease Assessment Scale" in a Brazilian sample.

Schultz RR, Siviero MO, Bertolucci PH.

Braz J Med Biol Res. 2001 Oct;34(10):1295-302.

20.

Sensitivity and test-retest reliability of the international shopping list test in assessing verbal learning and memory in mild Alzheimer's disease.

Thompson TA, Wilson PH, Snyder PJ, Pietrzak RH, Darby D, Maruff P, Buschke H.

Arch Clin Neuropsychol. 2011 Aug;26(5):412-24. doi: 10.1093/arclin/acr039. Epub 2011 May 25.

PMID:
21613302

Supplemental Content

Support Center